E3 ubiquitin ligase SYVN1 as a promising therapeutic target for diverse human diseases by Li Zhu, Yong-Ping Liu, Yuan-Wang, Bo-Xuan Sun, Yu-Ting Huang, Ji-Kai Zhao, Jian-Feng Liu, Li-Ming Yu, Hui-Shan Wang

“…These important findings provide new avenues for further investigation of SYVN1 protein, new insights into potential strategies to prevent and treat human diseases, and new directions for future drug development.…”
Get full text

Effects of the Paediatric Regulation funding on the development of off-patent medicines in children by Lucia Ruggieri, Silvia Torretta, Viviana Giannuzzi, Alessandra Natale, Mariagrazia Felisi, Adriana Ceci, Adriana Ceci, Fedele Bonifazi

“…A survey to project coordinators was also conducted to explore the challenges faced during paediatric drug development plans.ResultsThe 20 FP7-funded projects studied 24 off-patent active substances. …”
Get full text

Polydatin enhances oxaliplatin-induced cell death by activating NOX5-ROS-mediated DNA damage and ER stress in colon cancer cells by Qi Zhao, Qi Zhao, Qi Zhao, Yan Zhang, Yan Zhang, Jieyu Liu, Peipei Chen, Annabeth Onga, Namki Cho, Ri Cui, Chenguo Zheng

Get full text

Pharma TARP: A Troubled Asset Relief Program for Novel, Abandoned Projects in the Pharmaceutical Industry by Tamas Bartfai, Graham Vaughan Lees

“…Pfizer alone will close well over a hundred drug development projects that have reached two-thirds of the way to launch. …”
Get full text

Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints. by Elias Laurin Meyer, Peter Mesenbrink, Nicholas A Di Prospero, Juan M Pericàs, Ekkehard Glimm, Vlad Ratziu, Elena Sena, Franz König, EU-PEARL NASH Investigators

“…Platform trials provide great benefits for sponsors and trial participants in terms of accelerating drug development programs. In this article, we describe some of the activities of the EU-PEARL consortium (EU Patient-cEntric clinicAl tRial pLatforms) regarding the use of platform trials in NASH, in particular the proposed trial design, decision rules and simulation results. …”
Get full text

The Use of Generic Medications for Glaucoma by Andrew J. Tatham

“…Other potential problems with generic eye drops include differences in bottle design affecting adherence, problems with supply, and the possibility that reduced revenue for innovator companies will lead to reduced investment in new drug development. This article reviews the potential advantages and disadvantages of generic antiglaucoma medications.…”
Get full text

Interactions between Bacteriophages and Eukaryotic Cells by Ramendra Dirgantara Putra, Diana Lyrawati

“…With the advancement and combination of in silico, in vitro, and in vivo approaches and clinical trials, bacteriophages definitely serve as useful repertoire for biologic target-based drug development to manage many complex diseases in the future.…”
Get full text

Intestinal inflammation in TNBS sensitized rats as a model of chronic inflammatory bowel disease by N. Selve, T. Wöhrmann

“…The applicability and relevance of this new model are discussed with respect to drug development and basic research of inflammatory bowel diseases.…”
Get full text

Patient-derived induced pluripotent stem cell organoids for amyotrophic lateral sclerosis drug discovery by Wenyan Li, Jingqi Liu, Wenting Li, Lina Sun, Hao Zhang, Lei Gao, Chong Gao

“…Growing evidence highlights the advantages of organoids in replicating ALS phenotypes and supporting drug development. However, challenges remain in utilizing organoids for ALS drug testing and other neurodegenerative diseases. …”
Get full text

A comprehensive review on the plant sources, pharmacological activities and pharmacokinetic characteristics of Syringaresinol by Lei Zhang, Yuqing Tian, Lingling Zhang, Huanyu Zhang, Jinghua Yang, Yi Wang, Na Lu, Wei Guo, Liang Wang

“…Additionally, we explored the pharmacokinetics, toxicology, and drug development aspects of Syringaresinol to guide future research efforts. …”
Get full text

Systematic review and quantitative meta-analysis of age-dependent human T-lymphocyte homeostasis by Victoria Kulesh, Victoria Kulesh, Kirill Peskov, Kirill Peskov, Kirill Peskov, Gabriel Helmlinger, Gennady Bocharov, Gennady Bocharov, Gennady Bocharov

Get full text

Advanced 3D bioprinted liver models with human-induced hepatocytes for personalized toxicity screening by Yue Ma, Runbang He, Bo Deng, Miaomiao Luo, Wenjie Zhang, Lina Mao, Wenxiang Hu, Yilei Mao, Huayu Yang, Pengyu Huang

“…The development of advanced in vitro models for assessing liver toxicity and drug responses is crucial for personalized medicine and preclinical drug development. 3D bioprinting technology provides opportunities to create human liver models that are suitable for conducting high-throughput screening for liver toxicity. …”
Get full text

Digital Twins of Biological Systems: A Narrative Review by Ghufran A. Alsalloum, Nour M. Al Sawaftah, Kelly M. Percival, Ghaleb A. Husseini

“…The influence of DTs extends beyond healthcare and can revolutionize healthcare management, drug development, clinical trials, and various biomedical research fields…”
Get full text

Solid-State FTIR Spectroscopic Study of Two Binary Mixtures: Cefepime-Metronidazole and Cefoperazone-Sulbactam by Hassan Refat H. Ali, Ramadan Ali, Hany A. Batakoushy, Sayed M. Derayea

“…The structural information of the pharmaceuticals and insights on the modes of molecular interactions are very important aspects in drug development. In this work, two cephalosporins and antimicrobial combinations, cefepime-metronidazole and cefoperazone-sulbactam, were studied in the solid state using FTIR spectroscopy for the first time. …”
Get full text

Structure-Function of Falcipains: Malarial Cysteine Proteases by Kailash C. Pandey, Rajnikant Dixit

“…Overall, the complexes of falcipain-2 and falcipain-3 with small and macromolecular inhibitors provide structural insight to facilitate the design or modification of effective drug treatment against malaria. Drug development targeting falcipains should be aided by a strong foundation of biochemical and structural studies.…”
Get full text

Fortifying Biosafety in Nigeria: Insights and Transformative Practices from the SNL-NIBSA Bio-risk Management Course by Ishaku Leo Elisha, Ahmed Waleed Joyan

Get full text

Bhavana, an Ayurvedic Pharmaceutical Method and a Versatile Drug Delivery Platform to Prepare Potentiated Micro-Nano-Sized Drugs: Core Concept and Its Current Relevance by Rohit Sharma, Prashant Bedarkar, Deepak Timalsina, Anand Chaudhary, Pradeep Kumar Prajapati

“…A comprehensive review was performed on the core concepts of Bhavana, alongside its possible pharmacotherapeutic effects and relevance in drug development, by probing Ayurvedic claims in light of published pharmaceutical, analytical, and pharmacological reports. …”
Get full text

Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population by Andrew E. Stine, Jignesh Parmar, Amy K. Smith, Zachary Cummins, Narasimha Rao Pillalamarri, R. Joseph Bender

“…Abstract Challenges in drug development for rare diseases such as pulmonary arterial hypertension can be addressed through the use of mathematical modeling. …”
Get full text

2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses by Serban Georgeta

“…The chemical, physical and pharmacokinetic properties recommend 1,3,4-thiadiazole ring as a target in drug development. Many scientific papers report the antiparasitic potential of 2-amino-1,3,4-thiadiazoles. …”
Get full text

The Discovery of Novel Experimental Therapies for Inflammatory Arthritis by Charles J. Malemud

“…Over the past few years, sphingosine-1-phosphate, interleukin-7 receptor, spleen tyrosine kinase, extracellular signal-regulated kinase, mitogen-activated protein kinase 5/p38 kinase regulated/activated protein kinase, micro-RNAs, tumor necrosis factor-related apoptosis inducing ligand and the polyubiquitin-proteasome pathway were identified as promising novel targets for potential antiarthritis drug development. Indeed several experimental compounds alter the biological activity of these targets and have shown clinical efficacy in animal models of arthritis. …”
Get full text